Genitourinary Cancers

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses an analysis of the CheckMate-214 study in advanced renal cell carcinoma (RCC).

Thomas Powles MBBS, MRCP, MD, professor of Genitourinary Oncology, lead, Solid Tumour Research, Barts Cancer Institute, director, Barts Cancer Centre, discusses biomarkers for immunotherapy in bladder cancer.

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses biomarkers in renal cell carcinoma.

Jonathan E. Rosenberg, MD, discusses the extended follow-up of the CheckMate-032 study, as well as the future of immunotherapy in urothelial carcinoma.

Peter E. Clark, MD, discusses the role of surgery in the rapidly evolving treatment paradigm for patients with renal cell carcinoma.

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the molecular characteristics of patients with renal cell carcinoma (RCC) enrolled on the IMmotion151 study.

As researchers gain a better understanding of the unique aspects of individual tumor types and their surrounding microenvironment, the design of novel therapies categorized as prodrugs is become increasingly sophisticated, and several novel constructs show particular promise.

The VEGF inhibitor tivozanib reduced the risk of disease progression or death by 26% compared with sorafenib in patients with highly refractory advanced or metastatic RCC, according to topline findings from the phase III TIVO-3 trial.

Joshua J. Meeks, MD, PhD, assistant professor of urology, Northwestern University Feinberg School of Medicine, discusses the mutations associated with T1 progression in bladder cancer.

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses methods of evaluating response to immunotherapy in renal cell carcinoma (RCC).

Claud M. Grigg, Jr, MD, discusses the evolving treatment options in the frontline setting for patients with renal cell carcinoma.

Ronald de Wit, MD, PhD, discusses the clinical implications of pembrolizumab in the non–muscle invasive bladder cancer patient population.

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses PD-L1 testing in patients with bladder cancer.

Asim Amin, MD, discusses the current role of checkpoint inhibitors in advanced renal cell carcinoma and where the future is heading in this space.

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses how to manage toxicities associated with immunotherapy and tyrosine kinase inhibitor combinations in renal cell carcinoma.

Claud Grigg, MD, medical oncologist, Levine Cancer Institute, discusses the future treatment landscape of renal cell carcinoma (RCC).

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses immunotherapy combinations in kidney cancer.

An interim analysis of an ongoing single-arm open-label phase II study showed encouraging antitumor activity with pembrolizumab (Keytruda) in patients with high-risk nonmuscle invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin.

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses next steps with immunotherapy in the treatment of patients with advanced renal cell carcinoma.

The poor long-term survival outcomes for patients with advanced renal cell carcinoma have prompted intensive clinical research aimed at developing novel therapeutic options addressing unmet needs.

Claud Grigg, MD, medical oncologist, Levine Cancer Institute, discusses frontline tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC).

Extended follow-up data from the CheckMate-032 study shows a trend toward higher overall response and longer progression-free survival with the regimen of nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg in patients with platinum-pretreated metastatic urothelial carcinoma.

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

The combination of avelumab and axitinib doubled objective response rates and significantly improved progression-free survival compared with sunitinib in patients with treatment-naïve advanced renal cell carcinoma regardless of PD-L1 expression.